Celcuity Surges 16% on Promising Breast Cancer Drug Data
Celcuity shares jumped 16% after its lead drug candidate, gedatolisib, met the primary endpoint in a Phase 3 breast cancer trial for PIK3CA-mutant tumors, setting the stage for a supplemental FDA filing.
Markets
